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Sarcoidosis  is  a  multi-system  granulomatous  disease  of  unclear  etiology  with  variable 
presentation. The common sites of involvement include the lungs and the lymphnodes, though 
many other organs including liver, spleen, skin, eyes, and even the heart can get involved. The 
pathological hallmark of this disease is a non-caseating granuloma.                                      
The prevalence of cardiac involvement in patients with systemic sarcoidosis ranges from 3.7 to 
54.9%  depending  on  the  population  studied  (asymptomatic  or  symptomatic),  imaging 
techniques  used  and  criteria  used  for  diagnosis.[1]  Though  cardiac  involvement  may  be 
asymptomatic,  common  cardiac  manifestations  include  conduction  abnormalities  usually 
complete atrioventricular block, ventricular arrhythmias, heart failure, atrial tachyarrhythmias 
and sudden cardiac death. Rarely, isolated cardiac sarcoidosis without manifestations related to 
other organs occurs and presents difficulties in the diagnosis. Since the yield of endomyocardial 
biopsy for cardiac sarcoidosis is low, due to patchy and focal involvement of myocardium, the 
diagnosis of cardiac sarcoidosis is often made by presence of cardiac manifestations along with 
tissue diagnosis from other organs. No international consensus guidelines or diagnostic criteria 
for cardiac sarcoidosis exist except for the Japanese Ministry of Health and Welfare Criteria.
[2,3] To compound the difficulties with the diagnosis, tuberculosis affecting the heart can have 
very  similar  clinical  [ventricular  tachycardia  (VT),  lymphnode  enlargement],  radiological 
(mediastinal  adenopathy,  lung lesions) and imaging features [(mid myocardial  scar, delayed 
enhancement on magnetic resonance imaging (MRI) or focal uptake of 18flouro-deoxyglucose 
(FDG)  on  positron  emission  computerized  tomography  (PET CT)].  The  histology  showing 
caseating granulomas (in lung or node biopsy) or positive stain or culture for acid-fast bacilli 
and/or positive DNA-PCR for Mycobacterium tuberculosis in the tissue can indicate the correct 
diagnosis of tuberculosis and guide appropriate disease specific therapy.[4] The differentiation 
is important since steroid administration without anti-tubercular therapy can result in flaring of 
the tuberculosis if underlying tuberculosis was present.  A high index of suspicion is essential 
for the diagnosis of both tuberculosis and sarcoidosis of the heart. There is also a possibility of 
co-existence of the two diseases  (tuberculosis-sarcoidosis overlap),  especially  in developing 
countries  like  India  with high  prevalence  of  tuberculosis.                                
 Even when the diagnosis  is  confirmed,  the treatment  of  cardiac  sarcoidosis  poses  a  lot  of 
challenges to the clinician. Though, atrioventricular block, the most common manifestation of 
cardiac sarcoidosis, may reverse with steroid and/or immunosuppressive therapy, the recurrence 
rate is very high and pacemaker implantation is almost always needed.[5] The management of 
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VT is even more complex as has been shown in the case report published by Ajay M Naik et al.
[6] in this issue of the journal. The VTs in cardiac sarcoidosis are usually monomorphic and 
rarely polymorphic. However, spontaneous or inducible monomorphic VTs of multiple QRS 
morphologies  indicating  different  exit  sites  or  multiple  reentrant  circuits  due  to  patchy 
myocardial involvement are often present. The pathogenesis of these VTs relates to either acute 
granulomatous inflammation in the myocardium seen in the early active phase of sarcoidosis or 
late  myocardial  scarring  in  the  inactive  phase  of  the  disease.  Interestingly,  both  healed 
granulomas and varying degrees of active inflammation may co-exist producing a heterogenous 
substrate that is unique to this disease.[7] The disease specific therapy including corticosteroids 
and  steroid  sparing  immunosuppressive  agents  (like  methotrexate,  azathioprine, 
cyclophosphamide,  infliximab,  anti-malarials,  and  thalidomide)  is  likely  to  reduce  the  VT 
occurrence during the active inflammatory phase but unlikely to help in the late scar related 
reentrant VTs. The reports of radiofrequency (RF) ablation for VT in cardiac sarcoidosis have 
been mixed – with some reporting good results and others reporting poor efficacy.[8,9] Also, 
for it to be successful, both endocardial and epicardial approaches to ablation may be required 
in some cases.[8] It is logical that inflammation related VT during the active phase of sarcoid is 
likely to have poor result of RF ablation in absence of anti-inflammatory drug therapy, whereas 
scar related VT is likely to respond better to RF ablation. Knowing whether sarcoid is currently 
in  active  or  scar  phase is  itself  challenging.  Increased uptake  on FDG PET suggests  acute 
inflammation where as delayed enhancement on MRI indicates a scar. Role of high-sensitivity 
C reactive protein (hs-CRP), erythrocyte sedimentation rate (ESR) and angiotensin converting 
enzyme (ACE) levels to assess activity  is not well defined but may be useful in individual  
cases. Ajit Thachil et al. have proposed a working strategy for diagnosis and management of 
monomorphic VT due to granulomatous heart disease (sarcoidosis and tuberculosis).[4]        
Atrial  arrhythmias  are  uncommonly  seen  in  cardiac  sarcoidosis.[10]  Here  again,  the 
pathogenesis may involve both inflammation as well as scarring in the left and right atrium. The 
report of two cases of atrial flutter in patients with cardiac sarcoidosis by Namboodiri et al.[11] 
where in steroid therapy rendered the flutter non-inducible in the first case and facilitated the 
successful ablation in the second case with extensive left atrial scarring, again suggests a major 
role of inflammation in origin of arrhythmias in cardiac sarcoidosis. Similarly, the case report 
of Uma Srivatsa et al.[12] where cardiac sarcoidosis presented with atrial fibrillation (AF) and 
later  progressed  to  other  manifestations  like  AV  block,  myocardial  involvement  and 
cardiomyopathy also highlighted the interlink with inflammation and reduction of AF burden 
with anti-inflammatory disease specific therapy. The case series and reports of these nature and 
clinical  registries  are  very  important  for  understanding  the  clinical  patterns,  result  of 
investigations and guiding therapy in disorders like sarcoidosis where no large scale clinical 
studies  exist  and are  not  likely  to  be  possible  in  future  due  to  logistic  reasons.           
With increasing recognition of role of inflammation in cardiac arrhythmias, cardiac sarcoidosis 
provides an important interlink. As our understanding of inflammatory diseases affecting the 
heart like tuberculosis and sarcoidosis grows, more research on the inflammatory markers to 
guide therapy and on agents targeting inflammation for treatment  of cardiac arrhythmias  in 
these diseases is the need of the hour.                                                    
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